Newswire (Published: Wednesday, August 14, 2019, Received: Wednesday, August 14, 2019, 5:26:26 PM CDT)

Word Count: 465

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting originating from Edmonton, Canada, by NewsRx correspondents, research stated, “Active surveillance (AS) is the preferred primary treatment strategy for men with low-risk clinically localised prostate cancer (PCa); however, the majority of these men still receive radical treatment within 10 years due to disease progression and/or fear of cancer progression. Interventions designed to suppress tumor growth, mitigate fear of cancer progression and precondition men for impending radical treatments are an unmet clinical need.”

Funders for this research include Canadian Institutes of Health Research, Prostate Cancer Canada.

Our news editors obtained a quote from the research from the University of Alberta, “Exercise has been shown to delay the progression of prostate tumours in animal models, improve physical and functional health and manage psychological outcomes in cancer patients; however, these outcomes have not been demonstrated in PCa patients undergoing AS. This phase II randomised controlled trial will randomise 66 men undergoing AS to either an exercise group or a usual care group. The exercise group will perform a 12-week, supervised, high-intensity interval training programme, consisting of 3 sessions/week for 28-40 min/session. The primary outcome will be cardiorespiratory fitness. Secondary outcomes will include immunosurveillance and cancer-related biomarkers, psychosocial outcomes including fear of cancer progression and quality of life and physical function. Exploratory outcomes will include clinical indicators of disease progression. The trial has 80% power to detect a significant between-group difference in VO of 3.5 mL/kg/min with a two-tailed alpha level <0.05 and a 10% dropout rate. The study has received full ethical approval from the Health Research Ethics Board of Alberta -Cancer Committee (Protocol Number: HREBA.CC-17-0248).”

According to the news editors, the research concluded: “The findings of the study will be disseminated through public and scientific channels.”

For more information on this research see: Exercise duRing Active Surveillance for prostatE cancer-the ERASE trial: a study protocol of a phase II randomised controlled trial. Bmj Open, 2019;9(7):e026438. (BMJ Publishing Group -; Bmj Open -

The news editors report that additional information may be obtained by contacting D.W. Kang, Faculty of Kinesiology, Sport and Recreation, University of Alberta, Edmonton, AB, Canada. Additional authors for this research include A.S. Fairey, N.G. Boule, C.J. Field and K.S Courneya.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)


University of Alberta
BMJ Publishing Group Limited


Education and Instruction
      Higher Education


North America


Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
            Pharmaceutical Development
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
                  Clinical Trial Events
                        Clinical Trials - Phase 2
                  Drug Testing and Approval Process
      Health Policy and Debates
      Treatments and Therapies
            Medicinal Drugs
                  Drug Testing and Approval Process
Trading Impact
      Drug and Device Regulatory Impact
            Clinical Trial Events
                  Clinical Trials - Phase 2
Life and Society